Animal Models of Lassa Fever
Lassa virus (LASV), the causative agent of Lassa fever, is estimated to be responsible for up to 300,000 new infections and 5000 deaths each year across Western Africa. The most recent 2018 and 2019 Nigerian outbreaks featured alarmingly high fatality rates of up to 25.4%. In addition to the severit...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Pathogens |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-0817/9/3/197 |
id |
doaj-0e267a07f576425f89a2a2b4251ee843 |
---|---|
record_format |
Article |
spelling |
doaj-0e267a07f576425f89a2a2b4251ee8432020-11-25T02:06:32ZengMDPI AGPathogens2076-08172020-03-019319710.3390/pathogens9030197pathogens9030197Animal Models of Lassa FeverRachel A. Sattler0Slobodan Paessler1Hinh Ly2Cheng Huang3Department of Pathology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-0609, USADepartment of Pathology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-0609, USADepartment of Veterinary Biomedical Sciences, University of Minnesota, Twin Cities, 1988 Fitch Ave., 295H Animal Science Veterinary Medicine Bldg., Saint Paul, MN 55108, USADepartment of Pathology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-0609, USALassa virus (LASV), the causative agent of Lassa fever, is estimated to be responsible for up to 300,000 new infections and 5000 deaths each year across Western Africa. The most recent 2018 and 2019 Nigerian outbreaks featured alarmingly high fatality rates of up to 25.4%. In addition to the severity and high fatality of the disease, a significant population of survivors suffer from long-term sequelae, such as sensorineural hearing loss, resulting in a huge socioeconomic burden in endemic regions. There are no Food and Drug Administration (FDA)-approved vaccines, and therapeutics remain extremely limited for Lassa fever. Development of countermeasures depends on relevant animal models that can develop a disease strongly mimicking the pathogenic features of Lassa fever in humans. The objective of this review is to evaluate the currently available animal models for LASV infection with an emphasis on their pathogenic and histologic characteristics as well as recent advances in the development of a suitable rodent model. This information may facilitate the development of an improved animal model for understanding disease pathogenesis of Lassa fever and for vaccine or antiviral testing.https://www.mdpi.com/2076-0817/9/3/197arenaviruseslassa virusviral hemorrhagic feverslassa feveranimal models |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rachel A. Sattler Slobodan Paessler Hinh Ly Cheng Huang |
spellingShingle |
Rachel A. Sattler Slobodan Paessler Hinh Ly Cheng Huang Animal Models of Lassa Fever Pathogens arenaviruses lassa virus viral hemorrhagic fevers lassa fever animal models |
author_facet |
Rachel A. Sattler Slobodan Paessler Hinh Ly Cheng Huang |
author_sort |
Rachel A. Sattler |
title |
Animal Models of Lassa Fever |
title_short |
Animal Models of Lassa Fever |
title_full |
Animal Models of Lassa Fever |
title_fullStr |
Animal Models of Lassa Fever |
title_full_unstemmed |
Animal Models of Lassa Fever |
title_sort |
animal models of lassa fever |
publisher |
MDPI AG |
series |
Pathogens |
issn |
2076-0817 |
publishDate |
2020-03-01 |
description |
Lassa virus (LASV), the causative agent of Lassa fever, is estimated to be responsible for up to 300,000 new infections and 5000 deaths each year across Western Africa. The most recent 2018 and 2019 Nigerian outbreaks featured alarmingly high fatality rates of up to 25.4%. In addition to the severity and high fatality of the disease, a significant population of survivors suffer from long-term sequelae, such as sensorineural hearing loss, resulting in a huge socioeconomic burden in endemic regions. There are no Food and Drug Administration (FDA)-approved vaccines, and therapeutics remain extremely limited for Lassa fever. Development of countermeasures depends on relevant animal models that can develop a disease strongly mimicking the pathogenic features of Lassa fever in humans. The objective of this review is to evaluate the currently available animal models for LASV infection with an emphasis on their pathogenic and histologic characteristics as well as recent advances in the development of a suitable rodent model. This information may facilitate the development of an improved animal model for understanding disease pathogenesis of Lassa fever and for vaccine or antiviral testing. |
topic |
arenaviruses lassa virus viral hemorrhagic fevers lassa fever animal models |
url |
https://www.mdpi.com/2076-0817/9/3/197 |
work_keys_str_mv |
AT rachelasattler animalmodelsoflassafever AT slobodanpaessler animalmodelsoflassafever AT hinhly animalmodelsoflassafever AT chenghuang animalmodelsoflassafever |
_version_ |
1724933348526129152 |